Infliximab-dyyb, the active ingredient in INFLECTRA, is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions) specific for human tumor necrosis factor-alpha (TNFα). It has a molecular weight of approximately 149.1 kilodaltons. Infliximab-dyyb is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that includes measures to inactivate and remove viruses.

Inflectra Info

INFLECTRA for injection is supplied as a sterile, white, lyophilized powder for intravenous infusion. Following reconstitution with 10 mL of Sterile Water for Injection, USP, the resulting pH is approximately 7.2. Each single-use vial contains 100 mg infliximab-dyyb, 500 mg sucrose, 0.5 mg polysorbate 80, 2.2 mg sodium dihydrogen phosphate monohydrate, and 6.1 mg di-Sodium hydrogen phosphate dihydrate.

Inflectra Side Effects

The most common side effects include: 

  • upper respiratory infections
  • sinus infections
  • runny or stuffy nose
  • sore throat
  • cough
  • bronchitis
  • infusion-related reactions
  • headache
  • abdominal pain
  • nausea
  • diarrhea
  • indigestion
  • rash
  • itching
  • fatigue
  • pain
  • fever
  • oral thrush
  • joint pain
  • urinary tract infection, and
  • high blood pressure (hypertension)


Patient Assistance Programs

There are several programs patients can sign up for that will assist in treatment costs:


To learn more about this treatment, browse the resources below.

Order Form

To download the order form for this treatment, click below.

Ready to get started?

Contact us to chat with one of our helpful scheduling specialists!